- NASDAQ:VXRT gains 8.66% on Wednesday, as the micro-cap biotech industry rises.
- Operation Warp Speed funding to Johnson and Johnson gives investors hope of further payouts.
- Vaxart has a substantial war-chest to conduct a COVID-19 vaccine trial.
NASDAQ:VXRT has added to its recent surge, gaining 8.66% on Wednesday and closing the trading session at $9.66. The share price peaked after an early morning bump up to $10.99, but Vaxart spent the remainder of the day steadily declining. As with many of their rivals in the race to find a COVID-19 vaccine, Vaxart has seen its price increase by well over 2,500% so far this year, – pushing the firm’s market cap to over $1 billion. With the firm’s quarterly earnings call scheduled for next week – investors hope to hear news on the success of their vaccine in clinical development.
Update 2: VXRT shares are soaring on Friday, trading around $9.30 after hitting a daily high of $10.20. Earnings are keeping shares bid while worries about competitors' vaccines may also be in play, especially those with links to China, as Sino-American tensions are deteriorating See Reports US to sanction Hong Kong leader Carrie Lam.
Update: Vaxart is set to kick off Friday's trading session with a substantial double-digit rebound, recapturing the $10 level. The veteran company sai it had $140 million in cash at the end of July and that is it is preparing to enter a Phase 1 clinical trial with its coronavirus vaccine candidate. The upbeat news is inspiring investors, despite fierce competition, from firms such as Novavax. See: NVAX, which has three reasons to rise.
The big news of the day in the coronavirus news space has been that Johnson and Johnson (NYSE:JNJ) has agreed to provide 100 million doses of their coronavirus vaccine to Americans by 2021. The deal with the federal government is estimated to be valued at $1 billion. With the global demand for a COVID-19 vaccine at an all-time high, investors are optimistic that other companies would also be receiving government funding for their vaccine candidates. While Vaxart has five versions of its oral vaccine still in clinical trials, the firm’s candidate was selected as one of the vaccines that may be provided to Americans in 2021. Adding Vaxart’s continued involvement with Johnson and Johnson on an influenza vaccine – it is becoming clear why investors are excited about this relationship.
Vaxart Stock Forecast
As its earnings call approaches, Vaxart investors will want to know about the prospects of its oral vaccine – and how close the company is to potential distribution. Nevertheless, investors would be wise to temper their expectations of the company, as most of the Operation Warp Speed funding could be given to big-name companies like Johnson and Johnson or Glaxosmithkline (NYSE:GSK) and Pfizer (NYSE:PFE) – the latter also agreed to a deal to provide vaccines to Canada.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds gains above 1.1100, Fed rate decision in focus
EUR/USD is holding gains above 1.1100 in the European session on Wednesday. A broadly weak US Dollar, amid increased bets of an outsized Fed rate cut and a cautiously optimistic market mood, underpins the pair. All eyes remain on the Fed policy verdict.
GBP/USD extends rebound above 1.3200 after UK inflation data
The GBP/USD rebound gains traction above 1.3200 in European trading on Wednesday. The data from the UK showed that the annual core CPI rose 3.6% in August, up from a 3.3% increase in July, and supported the GBP. Focus shifts to Fed policy decisions.
Gold pulls back ahead of Fed ruling
Gold hit a record high of $2,589 at the start of the week after market bets that the Fed would make a double-dose 0.50% cut to interest rates at its meeting later today rose sharply. A bigger rate cut from the Fed would be positive for Gold because it lowers the opportunity cost of holding the yellow metal, which is a non-interest-paying asset. This makes it more attractive to investors.
Federal Reserve set for first interest-rate reduction in four years amid growing bets of jumbo cut
The Federal Reserve is widely expected to lower the policy rate after the September meeting. The revised Summary of Economic Projections and Fed Chairman Powell’s remarks could provide important clues about the rate outlook.
UK CPI set to grow at stable 2.2% in August ahead of BoE meeting
The United Kingdom Office for National Statistics will release August Consumer Price Index figures on Wednesday. Inflation, as measured by the CPI, is one of the main factors on which the Bank of England bases its monetary policy decision, meaning the data is considered a major mover of the Pound Sterling.
Moneta Markets review 2024: All you need to know
VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.